Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Merck ’s pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for treating certain ...

Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total returns. See why MRK stock is a buy.

Merck & Co. is no longer a deep-value patent cliff trade but a fairly valued defensive compounder. Read why I have downgraded ...

The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency ...

Moderna (NASDAQ: MRNA) has been on fire this year, with the biotech's shares up by 39% through Feb. 6. This isn't due to the ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Chinese biotech Bio-Thera Solutions (SHE: 688177) has signed commercialization and license agreements with Saudi drugmaker ...

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...

Gilead Sciences reported positive Phase 3 results for Trodelvy combined with Keytruda in first-line PD-L1+ metastatic ...

Merck (NYSE:MRK) has invested $30 million for nearly a 10% stake in Eikon Therapeutics as Eikon moves toward an IPO. The ...